Rubius Therapeutics to acquire manufacturing facility in Smithfield, RI
Rubius Therapeutics announced that it has signed a purchase and sale agreement for the acquisition of a 135,000-square foot manufacturing facility located in Smithfield, Rhode Island. The company plans to invest up to $95M through 2020, and up to $155M in total over a five-plus year period, and it expects to hire approximately 150 people to be employed at the facility, pending the progression of its planned, staged investments. The company anticipates the purchase will close in the third quarter of 2018. The new facility will help the company scale its manufacturing process in order to produce large quantities of Red Cell Therapeutic product candidates and lentiviral vectors needed to encode biotherapeutic proteins inside or on the surface of each Red Cell Therapeutic. The facility will be customized to contain multiple manufacturing suites, which will enable Rubius to conduct its manufacturing operations in a cGMP compliant manner for clinical supply and, if approved, for the commercial supply of RCT product candidates. The first phase of the renovations is expected to be completed in approximately 24 months.